ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2537

Sjögren’s Disease and Non-Sjögren’s Sicca Patient Subsets Exhibit Cell Type-specific Transcriptional Dysregulations That May Identify Early Molecular Predictors of Disease Transition

James Li1, Chuang Li2, Bhuwan Khatri2, Anna Stolarczyk2, Kandice Tessneer2, Astrid Rasmussen2, Joel Guthridge2, Judith James2, Robert Hal Scofield2, He Li3, A. Darise Farris2, Kathy Sivils4 and Christopher Lessard2, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, 4Johnson & Johnson Innovative Medicine, Edmond, OK

Meeting: ACR Convergence 2024

Keywords: Gene Expression, Sjögren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Abstracts: Genetics, Genomics & Proteomics

Session Type: Abstract Session

Session Time: 1:00PM-2:30PM

Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disorder characterized by inflammatory destruction of the exocrine glands. SjD heterogeneity has been described through the presence or absence of the anti-SSA/Ro autoantibody. Previous studies examining whole blood of SjD patients reported transcriptional differences between SSA/Ro+ and SSA/Ro– subtypes. Here, we leveraged single-cell transcriptomics in peripheral blood mononuclear cells (PBMCs) to refine our understanding of cell type-specific variation in pathogenic pathways across different subpopulations of SjD patients.

Methods: PBMCs were isolated from human subjects with SjD, subjects with sicca symptoms not meeting SjD criteria, and healthy controls. Subjects were stratified into Groups 0-7 (Fig.1). 10X Genomics Chromium Single Cell RNA-sequencing was performed and sequencing data were demultiplexed using the 10X Genomics Cell Ranger (v 7.0.0) pipeline and aligned to the GRCh38 human genome. After quality control, 789,780 cells were integrated and clustered using Seurat1. Differential expression (DE) analyses were performed using NEBULA2. Significantly DE transcripts were input into Ingenuity Pathway Analysis (IPA).

Results: Our analyses confirmed previously reported overexpression of type 1 interferon (T1IFN)-related genes in the anti-SSA/Ro+ subset of SjD patients (group 7). Upregulation of T1IFN signaling was also present in patients who were anti-SSA/Ro+ but did not meet SjD criteria (group 4). In memory B cells, many pathways involving energy production, cellular proliferation, and cell migration were upregulated in groups 4 and 7 (Fig. 2A). Dysregulation of CD16 monocytes was primarily seen in groups 2, 4, and 5. An increase in S100 signaling was also observed in these groups. Group 4 displayed a unique CD16 monocyte transcriptional profile distinguished by increased activity in immunoregulatory pathways and decreased activity in chaperone-mediated autophagy and translation-coupled pathways (Fig. 2B). A different pattern emerged in CD14 monocytes – increased autophagy in group 4 but decreased autophagy in group 7. Outside of autophagy, CD14 monocytes showed similar trends in downregulation of common pathways in groups 4 and 7: IL-6, mTOR, and RAR activation among others (Fig. 2C). Most patient groups showed similar trends in NK cell dysregulation, where IL-10 and PPAR signaling were upregulated while IL-1, IL-12, IL-27, and many other pathways were downregulated (Fig. 2E).

Conclusion: Immune cells demonstrate cell type-specific dysregulation in key pathways governing the differentiation of unique cell types and regulation of immune responses, both in patients who meet SjD criteria and those with non-SjD sicca. Further analyses of shared underlying processes could help elucidate molecular predictors of the transition from early symptoms to confirmed disease.

References: 1. Satija, R. et al. Spatial reconstruction of single-cell gene expression data. Nature Biotechnology 33, 495-502 (2015); 2.    He, L. et al. NEBULA is a fast negative binomial mixed model for differential or co-expression analysis of large-scale multi-subject single-cell data. Commun Biol 4, 629 (2021). 

Supporting image 1

Figure 1. Schematic depicting application of the 2016 ACR/EULAR SjD criteria to subset n=135 subjects from the Oklahoma Sjögren’s Cohort into 8 subphenotype groups. ANA, anti-nuclear antibodies; OSS, Ocular Staining Score; WUSF, whole unstimulated salivary flow; FS, focus score.

Supporting image 2

Figure 2. Pathway analyses of differentially expressed (DE) transcripts revealed cell type- and patient group-specific dysregulation. Significantly DE transcripts (adjusted p<0.05) for each patient group compared to control (group 0) were analyzed by IPA. Plots show upregulated (red) and downregulated (blue) pathways in (A) memory B cells, (B) CD16 monocytes. (C) CD14 monocytes, (D) memory CD4 T cells, and (E) natural killer cells.


Disclosures: J. Li: None; C. Li: None; B. Khatri: None; A. Stolarczyk: None; K. Tessneer: None; A. Rasmussen: None; J. Guthridge: AstraZeneca, 5, Bristol-Myers Squibb(BMS), 5; J. James: GlaxoSmithKlein(GSK), 1, Progentec Diagnostics, Inc., 5, 10; R. Scofield: Johnson and Johnson Innovative Medicine, 1, Merck, 1; H. Li: Janssen Research & Development, LLC, 3, Johnson & Johnson, 11; A. Farris: Johnson and Johnson Innovative Medicine, 5; K. Sivils: Janssen Research & Development, LLC, 3, Johnson & Johnson, 11; C. Lessard: Johnson and Johnson Innovative Medicine, 2, 5, Johnson and Johnson Sjögren's Disease Advisory Board, 1.

To cite this abstract in AMA style:

Li J, Li C, Khatri B, Stolarczyk A, Tessneer K, Rasmussen A, Guthridge J, James J, Scofield R, Li H, Farris A, Sivils K, Lessard C. Sjögren’s Disease and Non-Sjögren’s Sicca Patient Subsets Exhibit Cell Type-specific Transcriptional Dysregulations That May Identify Early Molecular Predictors of Disease Transition [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/sjogrens-disease-and-non-sjogrens-sicca-patient-subsets-exhibit-cell-type-specific-transcriptional-dysregulations-that-may-identify-early-molecular-predictors-of-disease-transition/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/sjogrens-disease-and-non-sjogrens-sicca-patient-subsets-exhibit-cell-type-specific-transcriptional-dysregulations-that-may-identify-early-molecular-predictors-of-disease-transition/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology